China National Pharmaceutical Group Co., Ltd. (Sinopharm) announced on Saturday that its COVID-19 vaccine has acquired the certificate of Good Manufacturing Practice (GMP) issued by the Hungarian National Institute of Pharmacy and Nutrition (OGYEI).

China's Sinopharm COVID-19 vaccine is the first Chinese vaccine authorized for emergency use by the European Union and the first to be certified by OGYEI, according to a company statement.